美国生物医药公司Axsome周五宣布,该公司抗抑郁口服药Auvelity获得美国FDA批准,用于治疗成年人抑郁症(MDD),该药物预计于今年第四季度正式推出。 重度抑郁症的特征是持续的悲伤和自杀念头。美国该疾病的患者人群数量达到2000万。而全球抑郁症患者数量多达3亿,中国也有多达5000万抑郁症患者。 在药物获得批准后,Axsome公司股价大涨超过40%。过去一年中,Axsome股价累计...
Source Link美国生物医药公司Axsome周五宣布,该公司抗抑郁口服药Auvelity获得美国FDA批准,用于治疗成年人抑郁症(MDD),该药物预计于今年第四季度正式推出。 重度抑郁症的特征是持续的悲伤和自杀念头。美国该疾病的患者人群数量达到2000万。而全球抑郁症患者数量多达3亿,中国也有多达5000万抑郁症患者。 在药物获得批准后,Axsome公司股价大涨超过40%。过去一年中,Axsome股价累计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.